U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
Business Wire•21/10/2026•16:01 ET
0
Key Highlights
- ➤Turn Therapeutics to discuss GX-03 access strategy in atopic dermatitis
- ➤Virtual fireside chat scheduled for October 28, 2026, at 10:00 AM ET
- ➤GX-03 is being evaluated in atopic dermatitis and developed for onychomycosis
Expert Statements
Bradley Burnam, Chief Executive Officer of Turn Therapeutics
“Building a Program for Patient Access in Atopic Dermatitis”
Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead of Turn Therapeutics
“Building a Program for Patient Access in Atopic Dermatitis”
U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will join in a U.S. Bancorp | BTIG virtual fireside chat as follows:
Get started
Create a free account to read the full story.